Related references
Note: Only part of the references are listed.Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
A. Swaminath et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
Jean-Frederic Colombel et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease
Joel R. Rosh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease
Franca Viola et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Predictors of early response to infliximab in patients with ulcerative colitis
Marc Ferrante et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Predictors of response to infliximab in luminal Crohn's disease
D Laharie et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
M Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Long-term Treatment of Rectovaginal Fistulas in Crohn's Disease: Response to Infliximab in the ACCENT II Study
Bruce E. Sands et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
WJ Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
EV Loftus
GASTROENTEROLOGY (2004)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Crohn's disease: step up or top down therapy
SB Hanauer
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
DA Schwartz et al.
GASTROENTEROLOGY (2002)
The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
EV Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?
E Louis et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
